TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05057897

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AZD1222
Description: 10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AZD1222
Description: 10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AZD1222
Description: 10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AZD1222
Description: 10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AZD1222
Description: 10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AZD1222
Description: 10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6
Study: NCT05545384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate Azathioprine (1st attack)
Description: Patients randomized in Immediate Azathioprine group will benefit from immediate treatment with azathioprine. Treatment will be started at 2mg/kg or at 1mg/kg if the patient has a partial activity which would be increased slowly according the 6-TGN activity and clinical and biological tolerance at Week 2 for patient with partial activity or M1 for patient without TPMT activity deficit.~Only for patient with partial deficit and whose 6-TGN activity is low, azathioprine would be increased at 3mg/kg/d at Week 6 and without exceeding a total daily dose of 150 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate Rituximab (1st attack)
Description: Patients randomized in Immediate Rituximab group will benefit from immediate treatment with rituximab. Rituximab 375mg/m2 IV will be given at D1 and D15 and repeat every 6 months for 2 years.~Once the inclusion criteria are validated, the first injection will be performed according to the injection protocol (Annex 4). Fifteen day later, the second injection will be performed.~The next visit during a consultation with PI or his collaborators will be scheduled 1 week ± 2 days later, and patients will be advised to contact the PI if any neurologic symptoms or symptoms of adverse event occurs in the meantime.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients in this group will be treated according to standard care
Study: NCT04952909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShortCut™
Description: Splitting bioprosthetic aortic valve leaflets
Study: NCT05616910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide
Description: iNO will be provided by ventilator or nasal cannula for 4 hours each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide
Description: iNO will be provided by ventilator or nasal cannula for 4 hours each day.
Study: NCT06084637

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of autologous microfat
Description: A preparation of autologous microfat (5mL) will be injected intra-articularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of autologous platelet-rich plasma
Description: A preparation of autologous platelet-rich plasma (5mL) will be injected intra-articularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of autologous microfat and platelet-rich plasma
Description: A preparation of autologous platelet-rich plasma (5mL) and autologous microfat (5mL) will be injected intra-articularly.
Study: NCT05816343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Description: Orlistat is an inhibitor of gastric and pancreatic lipases and can reduce dietary fat absorption by 30%. Orlistat at a dose of 2 capsules (each containing 60 mg of active drug) three times a day with each meal (a total dose of 360 mg daily).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo at a dose of 2 capsules (each containing 60 mg placebo) three times a day with each meal (a total dose of 360 mg daily).
Study: NCT05683405

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment of peri-implantitis with mechanical debridement
Description: Non-surgical treatment of peri-implantitis with mechanical debridement .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment of peri-implantitis with air polishing
Description: Non-surgical treatment of peri-implantitis with air polishing
Study: NCT04784052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSP191
Description: Participants will receive a single IV dose at start of conditioning

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS Prodigy System
Description: The device used to remove the αβ+T cells from donor stem cell transplant before being given to the recipient

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depleted Stem Cell Transplant
Description: TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic cells will be administered by IV after completion of conditioning regimen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabbit Anti-Thymoglobulin (rATG)
Description: 3 consecutive daily doses of rATG will be given by IV during conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 4 consecutive daily doses of cyclophosphamid will be given by IV during conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 4 consecutive daily doses of fludarabine will be given by IV during conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1 dose of rituximab will be given at the end of conditioning
Study: NCT05171400

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palatal Wound
Description: With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Palatal Wound
Description: With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palatal Wound
Description: With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Palatal Wound treated with Silk Fibroin Film
Description: With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film and 4.0 silk sutures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Palatal Wound treated with Insulin-loaded Silk Fibroin Film
Description: With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film loaded with insulin and 4.0 silk sutures.
Study: NCT06791343

Intervention type: DIAGNOSTIC_TEST
Intervention: AI-Based Diagnostic and Prognostic Model
Description: This intervention involves an AI system that integrates multimodal data, including maternal health records, laboratory test results, and imaging data, to predict the risk of maternal and neonatal diseases. The system uses deep learning algorithms to provide real-time, accurate predictions, enabling early identification of health complications. By analyzing historical health data, the model aims to predict potential risks for both mothers and infants, improving early intervention and outcomes.

Intervention type: DIAGNOSTIC_TEST
Intervention: AI-Based Diagnostic and Prognostic Model
Description: This intervention involves an AI system that integrates multimodal data, including maternal health records, laboratory test results, and imaging data, to predict the risk of maternal and neonatal diseases. The system uses deep learning algorithms to provide real-time, accurate predictions, enabling early identification of health complications. By analyzing historical health data, the model aims to predict potential risks for both mothers and infants, improving early intervention and outcomes.
Study: NCT05110742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR.5/IL15-transduced CB-NK cells
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR.5/IL15-transduced CB-NK cells
Description: Given by IV
Study: NCT06302946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromuscular stimulation ,mindfulness breathing and traditional physiotherapy program
Description: Receive neuromuscular stimulation, mindfulness breathing, and a traditional physiotherapy program. The experimental group participants will receive neuromuscular electrical stimulation with Mindful breathing additionally traditional physiotherapy program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physiotherapy program
Description: participants in the control group perceived the traditional physiotherapy program
Study: NCT06789783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate Capsule
Description: 10mg/Kg twice a day, 150mg or 300mg Lithium Carbonate
Study: NCT06785779

Intervention type: OTHER
Intervention: Secukinmab
Description: This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.
Study: NCT05980169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SensoniQ Treatment Station
Description: The SensoniQ® Treatment Station is a chemotherapy chair with multiple transducers that release low- frequency sound waves to different points on the body in a preset frequency, distribution and time during a chemotherapy infusion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SensoniQ Treatment Station
Description: The SensoniQ® Treatment Station is a chemotherapy chair with multiple transducers that release low- frequency sound waves to different points on the body in a preset frequency, distribution and time during a chemotherapy infusion.
Study: NCT05084430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M032
Description: Starting at week four, patients will undergo treatment on the same day, and every three weeks thereafter, with intravenous infusion of 200mg of Pembrolizumab . A total of 3 combined doses of Pembrolizumab and M032 will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M032
Description: Starting at week four, patients will undergo treatment on the same day, and every three weeks thereafter, with intravenous infusion of 200mg of Pembrolizumab . A total of 3 combined doses of Pembrolizumab and M032 will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Starting at week four, patients will undergo treatment on the same day, and every three weeks thereafter, with intravenous infusion of 200mg of Pembrolizumab . A total of 3 combined doses of Pembrolizumab and M032 will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Starting at week four, patients will undergo treatment on the same day, and every three weeks thereafter, with intravenous infusion of 200mg of Pembrolizumab . A total of 3 combined doses of Pembrolizumab and M032 will be given.
Study: NCT05622708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Treatment Period 1: Open-label secukinumab 150 mg PFS s.c. at baseline, Weeks 1, 2, 3 and 4 followed by administration every four weeks up to Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Treatment Period 2: Double-blind placebo PFS s.c. every 4 weeks from Week 56 to Week 116.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Treatment Period 2: Double-blind secukinumab 150 mg PFS s.c. every 4 weeks from Week 56 to Week 116.~Escape re-treatment (during Treatment Period 2): Open-label secukinumab 150 mg PFS s.c.
Study: NCT06551324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06821497
Description: 875 mg BID (2 times a day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2 IV (every 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: 160 mg QD
Study: NCT06785350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.012%diprospan+0.5%ropivacaine
Description: At the preoperative visit, patients will sign informed consent and learn to use the patient-controlled analgesia (PCA) pump and assess pain with the visual analogue scale (VAS). Standard general anesthesia will be induced and maintained with sufentanil, propofol, cisatracurium or rocuronium, and sevoflurane. Before incision, neurosurgeons will administer the allocated local infiltration solution. 0.5ml of diprospan will be diluted to 30 ml with 15 ml of ropivacaine in 0.9% NaCl to prepare diprospan at concentrations of 0.012%, respectively. The surgeon will use a 22 G straight needle for local infiltration anesthesia near the planned incisions. Postoperatively, patients will receive tropisetron and a PCA pump delivering sufentanil and ondansetron. PCA usage (effective/ineffective presses) and supplemental analgesia with Tylenol or loxoprofen will be monitored for 48 hours and up to 3 months. Dosages and intraoperative parameters will be closely recorded throughout.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.009%diprospan+0.5%ropivacaine
Description: At the preoperative visit, patients will sign informed consent and learn to use the patient-controlled analgesia (PCA) pump and assess pain with the visual analogue scale (VAS). Standard general anesthesia will be induced and maintained with sufentanil, propofol, cisatracurium or rocuronium, and sevoflurane. Before incision, neurosurgeons will administer the allocated local infiltration solution. 0.375ml of diprospan will be diluted to 30 ml with 15 ml of ropivacaine in 0.9% NaCl to prepare diprospan at concentrations of 0.009%, respectively. The surgeon will use a 22 G straight needle for local infiltration anesthesia near the planned incisions. Postoperatively, patients will receive tropisetron and a PCA pump delivering sufentanil and ondansetron. PCA usage (effective/ineffective presses) and supplemental analgesia with Tylenol or loxoprofen will be monitored for 48 hours and up to 3 months. Dosages and intraoperative parameters will be closely recorded throughout.
Study: NCT06204744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based GRASP program
Description: The home-based Graded Repetitive Arm Supplementary Program (GRASP) is designed to improve the upper extremity function for people with stroke, including exercises for stretching, coordination, arm and hand strengthening, and fine motor skills.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional occupational therapy home program
Description: The conventional OT home program will be prescribed by the occupational therapists, customizing stroke rehabilitation exercises to individual patient goals, with a primary focus on improving upper extremity function.
Study: NCT05306509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NiCE
Description: Participants will receive an initial conversation led by a trained senior nurse within eight weeks after initial oncologic diagnosis or relapse/recurrent disease diagnosis, with an introduction to the intervention and learning about the goals, values, hopes, and fears of each patient and family. The PPC team will then follow each patient by ongoing regular conversations (related to the child and family's conditions) led by the same nurse, every 4 weeks for six months, when symptom assessment and management, goal-directed supportive care, team collaboration, and care coordination will be delivered according to the family's needs. Increased PPC involvement, end-of-life care and bereavement care will be involved when necessary. If a participant feels any discomfort or distress during the intervention, a break will be taken until they feel better. If not, the central contact person will come and discussion about the participant's feeling and wiliness to continue the intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine PPC
Description: Participants will be scheduled to meet with the PPC team only when participants themselves, their families, or the attending oncologist requested an appointment.
Study: NCT06785480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer Controlled Local Anesthetic Delivery (CCLAD)
Description: Administering local anesthesia with 1.2ml Septanest normal (4% articaine, 1/200000 adrenaline) with CCLAD. The CCLAD device is set to 60sec/ml in continuous mode.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional metallic syringe
Description: A conventional metallic syringe is used to administers local anesthesia with 1.2ml Septanest normal (4% articaine, 1/200000 adrenaline).
Study: NCT05659030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: In order to develop the training material, first of all, a literature review will be made and a training booklet will be prepared. The training booklet will be submitted to expert opinion and a pilot application will be made by giving its final form. The training content is based on Pender's Health Promotion Model, which consists of 3 components.
Study: NCT05422703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: Skin-colored Kinesiology Tape (ARES tape,5 cm×5 m) is waterproof tape is made of 100% cotton,applied in the shape of a fan strip, waterproof. The width is 5 cm and thickness of 0.5 mm (5 cm×5 m ).This tape is sticking with a small stretch (about 15%).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gauze pack
Description: Place gauze pack over surgical site for one hour after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gauze pack
Description: Place gauze pack over surgical site for one hour after surgery.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ice pack
Description: Ice packs will be applied for 6 hours after surgery in all patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ice pack
Description: Ice packs will be applied for 6 hours after surgery in all patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: passive and active range of motion, stretching exercises, resistive mouth exercises, mobilization exercises and coordination exercices.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Analgesic
Description: NSAIDs like ibuprofen (600-800 mg) or declophenac sodium (50-150 mg) 3 times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesic
Description: NSAIDs like ibuprofen (600-800 mg) or declophenac sodium (50-150 mg) 3 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Proteolytic enzymes
Description: 1-2 ampoules daily IM box of 3 ampoules of 5 mg crystallized and lyophilized chymotrypsin (450 E. A. Units) + 3 ampoules of 3 ml apyrogenic saline for one week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proteolytic enzymes
Description: 1-2 ampoules daily IM box of 3 ampoules of 5 mg crystallized and lyophilized chymotrypsin (450 E. A. Units) + 3 ampoules of 3 ml apyrogenic saline for one week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mouth wash
Description: use 0.12% chlorhexidine or povidone iodine mouthwash daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouth wash
Description: use 0.12% chlorhexidine or povidone iodine mouthwash daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soft cold diet
Description: For the day of surgery
Study: NCT06475352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: Oxaliplatin will be administered at a fixed dose of 85 mg/m² by 2h intravenous (IV) infusion concurrently with folinic acid 400 mg/m² (or 200 mg/m² if L-folinic acid) as a 2 h IV infusion on day 1 of each 14-day cycle followed by 5-fluorouracil (5-FU) 400 mg/m² IV bolus on day 1, then continuous IV infusion of 1,200 mg/m² /day × 2 days (total 2400 mg/m² for 46-48 hours)
Study: NCT06019637

Intervention type: OTHER
Intervention: Onasemnogene Abeparvovec
Description: Retrospective and prospective observational study. There is no treatment allocation.
Study: NCT05267730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conectar Jugando Game Program
Description: Modern Board and Card Games as Cognitive Training in Rural Elementary Classrooms
Study: NCT04711902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: Secukinumab 150 mg was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AIN457
Description: Secukinumab 150 mg was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AIN457
Description: Secukinumab 150 mg was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Secukinumab Placebo
Description: Secukinumab placebo was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab Placebo
Description: Secukinumab placebo was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
Study: NCT06061263

Intervention type: OTHER
Intervention: follow up
Description: collecttion of clinicopathological data from a prespectively collected databse, including survival data.